1. Search Result
Search Result
Results for "

Anticoagulants

" in MedChemExpress (MCE) Product Catalog:

156

Inhibitors & Agonists

1

Screening Libraries

23

Biochemical Assay Reagents

16

Peptides

3

Inhibitory Antibodies

11

Natural
Products

12

Isotope-Labeled Compounds

7

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P2023

    Drug Derivative Others
    Hirugen is a derivative of hirudin, an anticoagulant protein found in leeches .
    Hirugen
  • HY-116913

    Thrombin Cardiovascular Disease
    Moxicoumone is an anticoagulant .
    Moxicoumone
  • HY-P1636

    Thrombin Cardiovascular Disease
    Hirudin (54-65) is a fragment of Hirudin with anticoagulant effects. Hirudin is a thrombin inhibitor with blood anticoagulant property .
    Hirudin (54-65)
  • HY-P1636A

    Thrombin Cardiovascular Disease
    Hirudin (54-65) TFA is a fragment of Hirudin with anticoagulant effects. Hirudin is a thrombin inhibitor with blood anticoagulant property .
    Hirudin (54-65) TFA
  • HY-151983

    Thrombin Cardiovascular Disease
    Thrombin inhibitor 6 is a potent thrombin inhibitor (IC50: 1 nM). Thrombin inhibitor 6 has the function as an anticoagulant .
    Thrombin inhibitor 6
  • HY-168712

    Factor Xa Cardiovascular Disease
    FXIa-IN-15 (Compound (S)-10h) is an inhibitor for Factor XIa (FXIa) and plasma kallikrein (PKa) with an IC50 of 0.38 nM and 59.2 nM. FXIa-IN-15 exhibits anticoagulant efficacy, that extends 50% activated partial thromboplastin time (aPTT) with EC1.5X of 0.55 μM .
    FXIa-IN-15
  • HY-P3649

    Biochemical Assay Reagents Cardiovascular Disease
    D-Val-Leu-Lys-chloromethylketone is a polypeptide containing three amino acids. D-Val-Leu-Lys-chloromethylketone can act as an anticoagulant .
    D-Val-Leu-Lys-chloromethylketone
  • HY-19442

    Thrombin Cardiovascular Disease
    Idrabiotaparinux, a derivative of Idraparinux (HY-19691), is a novel synthetic anticoagulant that links Idraparinux, a specific, indirect factor Xa inhibitor, to biotin .
    Idrabiotaparinux
  • HY-106561

    VD/VDR Cardiovascular Disease
    Tioclomarol, a coumarin anticoagulant, is a vitamin K antagonist .
    Tioclomarol
  • HY-114603

    LY 294468

    Thrombin Cardiovascular Disease
    Efegatran (LY 294468) is an inhibitor for thrombin, which inhibits aggregation of platelets, and exhibits anticoagulant and antithrombotic activities .
    Efegatran
  • HY-114603B

    LY 294468 dihydrochloride

    Thrombin Cardiovascular Disease
    Efegatran (LY 294468) dihydrochloride is an inhibitor for thrombin, which inhibits aggregation of platelets, and exhibits anticoagulant and antithrombotic activities .
    Efegatran di(hydrochloride)
  • HY-114603A

    LY 294468 sulfate

    Thrombin Cardiovascular Disease
    Efegatran (LY 294468) sulfate is an inhibitor for thrombin, which inhibits aggregation of platelets, and exhibits anticoagulant and antithrombotic activities .
    Efegatran sulfate
  • HY-163348

    Factor Xa Thrombin Cardiovascular Disease
    FXIIa-IN-4 (compound 22) is a potent, selective human FXIIa inhibitor with the IC50 of 0.032 μM, 0.30 μM, >50 μM for FXIIa, thrombin and FXIa, respectively. FXIIa-IN-4 can be used for study of anticoagulant .
    FXIIa-IN-4
  • HY-P2920

    Biochemical Assay Reagents Thrombin Bacterial Infection Cardiovascular Disease
    Protamine from salmon is a biochemical agent with antioxidant, antiheparin and antimicrobial activities. Protamine from salmon neutralizes the anticoagulant effect of heparin, thereby preventing the formation of antithrombin complexes in canine samples pretreated with heparin in vitro .
    Protamine from salmon
  • HY-111186

    WL 108366

    Glucocorticoid Receptor MMP VKOR Others
    Flocoumafen (WL 108366) is an orally active vitamin K epoxide reductase inhibitor and a multi-target ligand, which includes prostaglandin F synthase, serum albumin, glucocorticoid receptor 2, and MMP-9. Flocoumafen is a second-generation anticoagulant rodenticide (ARs) with a half-life of 177.4 hours and has deadly anticoagulant effects .
    Flocoumafen
  • HY-14936

    MCC-977

    Thrombin Cardiovascular Disease
    Sofigatran (MCC-977) is an orally active factor IIa (thrombin) inhibitor, acts as an anticoagulant. Sofigatran is used for the research of cardiovascular disease .
    Sofigatran
  • HY-E70171

    EC:2.8.2.23; HS3ST1

    Biochemical Assay Reagents Endocrinology
    Heparan Sulfate 3-O-Sulfotransferase 1 is a sulfotransferase. Heparan Sulfate 3-O-Sulfotransferase controls cellular production of the anticoagulant heparan sulfate related structure .
    Heparan Sulfate 3-O-Sulfotransferase 1
  • HY-W854549

    Fondaparinux free acid

    Factor Xa Cardiovascular Disease
    Heparin pentasaccharide (Fondaparinux) is a chemically synthesized selective factor Xa inhibitor with anticoagulant activity. Heparin pentasaccharide can be utilized in researches related to venous thromboembolic events .
    Heparin pentasaccharide
  • HY-108739

    BI 655075

    Thrombin Cardiovascular Disease
    Idarucizumab is a humanized monoclonal antibody fragment. Idarucizumab is first reversal agent for a direct oral anticoagulant (DOAC). Idarucizumab can specifically neutralize the effects of the oral direct thrombin inhibitor in order to restore hemostasis .
    Idarucizumab
  • HY-118803

    Factor Xa Others
    AS1468240 is an orally active inhibitor for anticoagulant factor Xa (fXa), that inhibits human fXa with IC50 of 8.7 nM. AS1468240 prolongs the coagulation time in mice .
    AS1468240
  • HY-P1929
    Bivalirudin
    5+ Cited Publications

    Thrombin Cardiovascular Disease
    Bivalirudin, a peptide anticoagulant, is a direct thrombin inhibitor for anticoagulation in the setting of invasive cardiology, particularly percutaneous coronary intervention .
    Bivalirudin
  • HY-111186R

    VKOR Glucocorticoid Receptor MMP Others
    Flocoumafen (Standard) is the analytical standard of Flocoumafen. This product is intended for research and analytical applications. Flocoumafen (WL 108366) is an orally active vitamin K epoxide reductase inhibitor and a multi-target ligand, which includes prostaglandin F synthase, serum albumin, glucocorticoid receptor 2, and MMP-9. Flocoumafen is a second-generation anticoagulant rodenticide (ARs) with a half-life of 177.4 hours and has deadly anticoagulant effects .
    Flocoumafen (Standard)
  • HY-10777

    Factor Xa Cardiovascular Disease
    EMD 495235 is a potent and orally active coagulation factor Xa inhibitor with an IC50 of 5.5 nM and a Ki of 6.8 nM. EMD 495235 shows anticoagulant activities .
    EMD 495235
  • HY-170485

    Thrombin Cardiovascular Disease
    Thrombin inhibitor 13 (Compound 13a) is a covalent and reversible inhibitor for thrombin (FIIa) with an IC50 of 0.7 nM. Thrombin inhibitor 13 prolongs the activated partial thromboplastin time (aPTT) and prothrombin time (PT), exhibits antithrombotic and anticoagulant activities .
    Thrombin inhibitor 13
  • HY-147393

    Ser/Thr Protease Cardiovascular Disease
    Factor VII-IN-1 (example 43) is a potent inhibitor of factor VII (FVII), with an IC50 of 1.1 μM. Factor VII-IN-1 shows anticoagulant properties .
    Factor VII-IN-1
  • HY-P991124

    Factor XI Cardiovascular Disease
    Cenvacibart is a monoclonal antibody with anticoagulant activity, targeting human coagulation factor XI (F11). Cenvacibart blocks the role of coagulation factor XI in the coagulation cascade, reducing thrombus formation. Cenvacibart is promising for research of thrombotic diseases .
    Cenvacibart
  • HY-17567C
    Heparin sodium salt (MW 15kDa)
    1 Publications Verification

    Sodium heparin (MW 15kDa); Sodium heparinate (MW 15kDa)

    Thrombin Factor Xa Autophagy Cardiovascular Disease
    Heparin sodium salt (MW 15kDa) (Sodium heparin (MW 15kDa)) is a polymer of Heparin with the molecular weight of 15kDa. Heparin sodium salt is an anticoagulant which binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin factor IIa and factor Xa .
    Heparin sodium salt (MW 15kDa)
  • HY-10722

    Factor Xa Cardiovascular Disease
    DX-9065a is a selective, nonpeptidic, and orally active factor Xa (FXa) inhibitor with a Ki of 41 nM for human FXa. DX-9065a has low activity against other serine proteases. DX-9065a has strong anticoagulant actions .
    DX-9065a
  • HY-W010169
    Sodium 4-aminobenzoate
    1 Publications Verification

    Biochemical Assay Reagents Others
    Sodium 4-aminobenzoate is a biochemical assay reagent. According to its structure, sodium 4-aminobenzoate exhibits antioxidant, anticoagulant, fubrinolytic and immunomodulating activities, and can be utilized as a protective agent against UV-irradiation and in diagnostic tests for the state of the gastrointestinal tract .
    Sodium 4-aminobenzoate
  • HY-132179
    Fucoidan
    2 Publications Verification

    Glycosidase Cardiovascular Disease Metabolic Disease Cancer
    Fucoidan, a biologically active polysaccharide, is an efficient inhibitor of α-amylase and α-glucosidase. Anticoagulant, antitumor, antioxidant and antisteatotic activities .
    Fucoidan
  • HY-14853

    YM150

    Factor Xa Ser/Thr Protease Cardiovascular Disease
    Darexaban (YM150) is a potent, selective and orally active factor Xa (FXa) inhibitor with an IC50 of 54.6 nM. Darexaban shows high selectivity against other related serine proteases, such as trypsin, thrombin, and kallikrein. Darexaban has anticoagulant and antithrombotic effects .
    Darexaban
  • HY-10594

    TAK-442

    Factor Xa Cardiovascular Disease Inflammation/Immunology
    Letaxaban (TAK-442) is an orally active and selective direct FXa inhibitor. Letaxaban is a drug with dual anticoagulant and anti-inflammatory activity that works by directly inhibiting FXa and by intervening in the PAR1 signaling pathway. Letaxaban can be used in the study of thrombotic diseases, cardiovascular diseases and inflammation-related diseases .
    Letaxaban
  • HY-10274
    Dabigatran etexilate
    3 Publications Verification

    BIBR 1048

    Thrombin Cardiovascular Disease
    Dabigatran etexilate (BIBR 1048) is an orally active proagent of Dabigatran (a direct inhibitor of thrombin). Dabigatran etexilate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation .
    Dabigatran etexilate
  • HY-10274A
    Dabigatran etexilate mesylate
    3 Publications Verification

    BIBR 1048MS; Dabigatran etexilate methanesulfonate

    Thrombin Cardiovascular Disease
    Dabigatran etexilate mesylate (BIBR 1048MS) is an orally active proagent of Dabigatran (a direct inhibitor of thrombin). Dabigatran etexilate mesylate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation .
    Dabigatran etexilate mesylate
  • HY-19674

    SSR182289A free base

    Thrombin Cardiovascular Disease
    SSR182289 (SSR182289A free base) is a selective and potent orally active thrombin inhibitor. SSR182289 competitively and selectivity inhibits human thrombin (Ki=0.031 μM). SSR182289 demonstrates anticoagulant activity in vitro (thrombin time EC100=96 nM) and inhibits tissue factor-induced thrombin generation (IC50=0.15 μM) in human plasma. SSR182289 inhibits thrombin-induced aggregation of human platelets (IC50=32 nM), but has no effect on aggregation induced by other platelet agonists .
    SSR182289
  • HY-150682

    Factor Xa Cardiovascular Disease
    FXIa-IN-9 (compound 3f) is a potent and selective FXIa inhibitor. FXIa-IN-9 can bind with FXIa and form hydrogen bond (human FXIa Ki: 0.17 nM, rabbit FXIa Ki: 0.5 nM). FXIa-IN-9 also has anticoagulant activity, and can be used in the research of thromboembolic diseases such as atrial fibrillation, stroke, myocardial infarction, deep vein thrombosis, and pulmonary embolism .
    FXIa-IN-9
  • HY-113958

    LM-2219

    VD/VDR Others
    Difethialone (LM-2219) is an anticoagulant rodenticide. Difethialone shows high rodenticide activity in warfarin-sensitive and resistant strains of rats and mice. Difethialone interferes with the circulation of vitamin K in the liver, preventing the synthesis of coagulation factors, resulting in the inability of the blood to coagulate properly, ultimately causing internal bleeding and death. Difethialone can be used in studies of ecological impacts .
    Difethialone
  • HY-P2813

    Thrombin Apoptosis Cardiovascular Disease Cancer
    Hirudin is a thrombin inhibitor with blood anticoagulant property. Hirudin has potent anti-thrombotic, wound repair, anti-fibrosis, anti-tumor and anti-hyperuricemia effects. Hirudin also affects diabetic complications, cerebral hemorrhage, and others .
    Hirudin
  • HY-P5875A

    Protease Activated Receptor (PAR) Cardiovascular Disease Inflammation/Immunology
    P4pal10 TFA is the TFA salt form of P4pal10 (HY-P5875). P4pal10 TFA is an antagonist for protease-activated receptor 4 (PAR4). P4pal10 TFA inhibits the platelet aggregation, inhibits tissue factor (TF)-induced thrombin generation, and exhibits anticoagulant and antithrombotic activities. P4pal10 TFA reduces the oedema and the granulocyte infiltration induced by Carrageenan (HY-125474). P4pal10 TFA ameliorates the injury in rats myocardial ischemia/reperfusion (I/R) models .
    P4pal10 TFA
  • HY-W105699

    Ethylenediaminetetraacetic acid tetrasodium tetrahydrate

    Biochemical Assay Reagents Others
    EDTA tetrasodium tetrahydrate is a metal chelator (binds to metal divalent and trivalent cations including calcium), which shows activities of anticoagulant and anti-hypercalcemic. EDTA tetrasodium tetrahydrate decreases the metal ion-catalyzed oxidative damage to proteins, and allows maintenance of reducing environment during protein purification. EDTA tetrasodium tetrahydrate can also decrease the formation of disulfide bonds .
    EDTA tetrasodium tetrahydrate
  • HY-162654

    Factor VIII Cardiovascular Disease
    FXIIIa-IN-1 (Compound 16) is a potent and selective FXIIIa (Factor XIIIa) inhibitor with an IC50 value of 2.4 μM. FXIIIa-IN-1 inhibits FXIIIa by competing with the Gln-donor protein substrate (dimethylcasein). FXIIIa-IN-1 holds promise for the development of effective and safe novel anticoagulants .
    FXIIIa-IN-1
  • HY-113958R

    TrxR Others
    Difethialone (Standard) is the analytical standard of Difethialone. This product is intended for research and analytical applications. Difethialone (LM-2219) is an anticoagulant rodenticide. Difethialone shows high rodenticide activity in warfarin-sensitive and resistant strains of rats and mice. Difethialone interferes with the circulation of vitamin K in the liver, preventing the synthesis of coagulation factors, resulting in the inability of the blood to coagulate properly, ultimately causing internal bleeding and death. Difethialone can be used in studies of ecological impacts .
    Difethialone (Standard)
  • HY-10274AR

    Thrombin Cardiovascular Disease
    Dabigatran etexilate (mesylate) (Standard) is the analytical standard of Dabigatran etexilate (mesylate). This product is intended for research and analytical applications. Dabigatran etexilate mesylate (BIBR 1048MS) is an orally active proagent of Dabigatran (a direct inhibitor of thrombin). Dabigatran etexilate mesylate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation .
    Dabigatran etexilate (mesylate) (Standard)
  • HY-10274R

    BIBR 1048 (Standard)

    Thrombin Cardiovascular Disease
    Dabigatran etexilate (Standard) is the analytical standard of Dabigatran etexilate. This product is intended for research and analytical applications. Dabigatran etexilate (BIBR 1048) is an orally active proagent of Dabigatran (a direct inhibitor of thrombin). Dabigatran etexilate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation[1].
    Dabigatran etexilate (Standard)
  • HY-116282
    Dextran sulfate sodium salt (MW 5000)
    1 Publications Verification

    DSS (MW 5000); DXS (MW 5000)

    HIV Complement System Apoptosis Infection Inflammation/Immunology
    Dextran sulfate sodium salt (DSS) (MW 5000) is a polymer of dehydrated glucose with a molecular weight of approximately 5000. Dextran sulfate sodium salt (DSS) with different molecular weights exhibits different biological activities. Dextran sulfate sodium salt (MW 5000) is an inhibitor of complement and coagulation pathways, and belongs to the glycosaminoglycans (GAG) family. Dextran sulfate sodium salt (MW 5000) acts as an anticoagulant, antiviral, and anti-lipemic agent. Dextran sulfate sodium salt (DSS) stops HIV-1 virus adsorption to host cells. Dextran sulfate sodium salt (MW 5000) prevents NK cell-mediated cytotoxicity. Dextran sulfate sodium salt (MW 5000) inhibits instant blood-mediated inflammatory reaction (IBMIR) .
    Dextran sulfate sodium salt (MW 5000)
  • HY-P4325

    Thrombin Others
    Hirudin (55-65) (sulfated) is a fragment of Hirudin with anticoagulant effects. Hirudin is a thrombin inhibitor with blood anticoagulant property.
    Hirudin (55-65) sulfated
  • HY-P1956A

    HSA (Cell culture grade, Endotoxin<0.125 EU/mg)

    NF-κB NO Synthase Cardiovascular Disease Inflammation/Immunology
    Human serum albumin (Cell culture grade, Endotoxin<0.125 EU/mg) (HSA) is the most abundant protein in plasma and is a major determinant of plasma oncotic pressure. Human serum albumin (Cell culture grade, Endotoxin<0.125 EU/mg) exhibits antioxidant, anticoagulant, anti-inflammatory, anti-platelet aggregation activities as well as colloid osmotic action. Human serum albumin (Cell culture grade, Endotoxin<0.125 EU/mg) can block the inhibitory effect of GML on human T cells, providing protective function for T cells. Human serum albumin (Cell culture grade, Endotoxin<0.125 EU/mg) is also associated with cardiovascular diseases and can partially prevent the LPS (HY-D1056) induced oxidative stress, as well as the upregulation of NF-κB, iNOS, and peroxynitrite (ONOO ) in the vascular wall, contributing to the reduction of blood pressure .
    Human serum albumin (Cell culture grade, Endotoxin<0.125 EU/mg)
  • HY-N7671

    Others Cardiovascular Disease
    Euphorbetin exhibits anticoagulant activities .
    Euphorbetin
  • HY-P1956
    Human serum albumin
    2 Publications Verification

    HSA

    NF-κB NO Synthase Cardiovascular Disease Inflammation/Immunology Cancer
    Human serum albumin (HSA) is the most abundant protein in plasma and is a major determinant of plasma oncotic pressure. Human serum albumin exhibits antioxidant, anticoagulant, anti-inflammatory, anti-platelet aggregation activities as well as colloid osmotic action. Human serum albumin can block the inhibitory effect of GML on human T cells, providing protective function for T cells. Human serum albumin is also associated with cardiovascular diseases and can partially prevent the LPS (HY-D1056) induced oxidative stress, as well as the upregulation of NF-κB, NF-κB, and peroxynitrite (ONOO ) in the vascular wall, contributing to the reduction of blood pressure .
    Human serum albumin
  • HY-B0325

    Rectadione

    VD/VDR Cardiovascular Disease
    Phenindione is an anticoagulant and can act as a vitamin K antagonist.
    Phenindione